Hepatitis B is a
noncytopathic virus, which exclusively replicates within the liver and affects
350 million people worldwide [1]. Chronic infection can lead to variable
disease manifestations such as cirrhosis, decompensated liver disease and
hepatocellular carcinoma causing 1 million deaths per year [2]. These important
clinical outcomes are a consequence of the host immune response to HBV, which
constitutes a double-edged sword responsible for both viral clearance and
hepatocellular damage.
The precipitants for natural history milestones such as
HBV-related hepatic flares (HF) and hepatitis B e Antigen (HBeAg)
seroconversion remain unknown. Virus-specific and non-specific cytotoxic T
lymphocytes (CTLs), T regulatory (Treg) cells, Natural Killer (NK), Natural
Killer T (NKT) cells and dendritic cells (DCs) have been postulated to play a
role [3]. The contribution of these immune cells and the nature of their
interaction in the immune pathogenesis of HBV-related liver disease require
further characterization. The logistical restraints of longitudinal, peripheral
and intrahepatic sampling of the human host as well as inadequate small animal
and cell culture models have hampered investigation of these immune mechanisms.
As a caveat to human based studies in HBV, the circulating immunological cells
may not reflect the phenotype and function of equivalent cells sequestered
within the human liver. Current knowledge about the immune response to HBV is
extrapolated from transgenic mouse models, many of which are models of viral
replication rather than liver injury.
Natural Killer (NK) and Natural Killer T (NKT) cells are
cytotoxic lymphocytes that constitute a key effector arm of the innate immune
system. Efforts to characterise the immunological determinants of Hepatitis B
virus (HBV) infection have focused on the adaptive immune system whilst
overlooking the potential interaction between virus, hepatocyte and NK or NKT
cells, which play an important role in host defense against viral pathogens
through direct cytotoxicity and the production of proinflammatory and immune
regulatory cytokines. There is debate as to whether NK or NKT cells are
effectors of antiviral activity or mediators of hepatic injury and fibrogenesis
in chronic hepatitis B infection. NK and NKT cells have been implicated in the
pathogenesis of liver disease due to other hepatotropic viruses such as
hepatitis C and E as well as autoimmune liver disease, as shown in animal
models of liver injury [4]. Human intrahepatic lymphocytes consist of 30%-50%
NK and 5-10% NKT cells. Peripheral blood lymphocytes contain 13% NK cells and
2% NKT cells [5]. The hepatic enrichment of NK and NKT cells reflects their
role as regulators at the interface between the innate and adaptive immune
response to liver disease. NK and NKT cells in the peripheral and intrahepatic
compartments share effector functions such as direct killing of viral-infected
cells and cytokine production. The latter is considered the more important
effector function in CHB [4]. NK and NKT cells demonstrate reciprocal
interactions (“crosstalk”) with hepatic macrophages, Kupffer cells (KC), DCs and
T cells as part of an amalgamated immune response to HBV [4].
The role of NK and NKT cells in the initiation and
orchestration of a dynamic host immune response against HBV-related liver
disease is investigated in this thesis. This hepatotrophic virus has evolved
direct and indirect strategies to evade or inhibit the large hepatic reservoir
of NK and NKT cells. In this thesis, I will focus on the dynamic phenotype and
function of NK and NKT cells throughout the different phases of HBV infection, which
so far have been poorly characterized. I will also examine the effect of
activated NK and NKT cells on liver injury, fibrosis, and their attenuation
following
HBV treatment, which remains controversial. Understanding the
role of NK and NKT cells in the pathogenesis of CHB may help to develop new
biomarkers for disease and treatment activity and design novel immunotherapies.